Hovione and Vertex partner for continuous manufacturing
Hovione is to host and operate a commercial-scale continuous manufacturing facility as part of an agreement with Vertex Pharmaceuticals
The facility will be installed in Hovione’s New Jersey location, and Hovione said it expects the project to be complete by the end of 2017 to support the future manufacturing of Vertex’s approved medicines.
With continuous manufacturing, raw materials used to produce oral medicines (tablets) are fed into a single, continuously running machine that includes real-time release testing and can create commercial-ready tablets in one day.
Continuous manufacturing is well suited for the production of precision medicines and those with breakthrough therapy designations where development timelines may be short and there are patients in urgent need of transformative new treatments, according to Hovione.
The new facility will include all facets of the continuous manufacturing process, including continuous blending, wet or dry granulation, fluid bed drying, tableting and coating operations.
Spare capacity will be offered to third parties who are interested in manufacturing medicines through this process.
Filipe Gaspar, VP R&D at Hovione, said: “This agreement enables Hovione to be at the forefront of an important evolution toward the use of continuous manufacturing and positions us as a reliable and innovative source for the production of new medicines.
“Like Vertex, we view continuous manufacturing as an important scientific advance and an important advance for patients, as the technology will allow us to run manufacturing and process development in parallel with clinical studies to more rapidly bring new medicines to those who need them.”
Guy Villax, CEO of Hovione, said: “Hovione and Vertex have been strong collaborators for more than a decade and share a commitment to innovative science.
“This agreement adds to a recently announced $24 million investment in our New Jersey facility. The entire expansion will double Hovione’s development and manufacturing capacity at that site.”